|
|
|
| Efficacy of Kuntai Capsule Adjuvant to Hormone Replacement Therapy in the Treatment of Premature Ovarian Failure |
| FAN Lili |
| Department of Pharmacy, the 83rd Group Army Hospital of the Chinese People's Liberation Army, Xinxiang Henan 453000 |
|
|
|
|
Abstract 【Objective】 To investigate the efficacy of Kuntai capsule as adjuvant therapy to hormone replacement therapy for premature ovarian failure. 【Methods】 A total of 100 patients with premature ovarian failure treated in the 83rd Group Army Hospital of the Chinese People's Liberation Army from January 2024 to December 2025 were enrolled and divided into control group (hormone replacement therapy) and observation group (Kuntai capsule combined with hormone replacement therapy) according to different treatment regimens, with 50 cases in each group. Hormone levels including estradiol (E2), follicle-stimulating hormone (FSH) and luteinizing hormone (LH), modified Kupperman index score, endometrial thickness, ovarian ultrasound indicators [mean ovarian diameter (MOD), antral follicle count (AFC), peak systolic velocity (PSV) of ovarian artery, resistance index (RI) and pulsatility index (PI)], and incidence of adverse reactions were compared between the two groups. 【Results】 After treatment, the level of E2 in the observation group was higher than that in the control group (P<0.05), while the levels of FSH and LH were lower than those in the control group (all P<0.05). After treatment, the modified Kupperman index score of the observation group was lower and endometrial thickness was thicker compared with the control group (all P<0.05). MOD, AFC and ovarian artery PSV in the observation group were higher (all P<0.05), whereas ovarian artery RI and PI were lower (all P<0.05). There was no statistically significant difference in the total incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】 Adjuvant treatment with Kuntai capsule combined with hormone replacement therapy can promote the recovery of hormone levels and improve ovarian function in patients with premature ovarian failure, with favorable safety profile.
|
|
Received: 09 March 2026
|
|
|
|
|
|
[1] 刘艳艳,马园园,黄向华,等. 不同来源间充质干细胞治疗卵巢早衰的机制[J]. 中国组织工程研究,2025,29(13):2764-2773.
[2] 王月,张骞文,潘可盈,等. 左归丸治疗卵巢早衰的研究进展[J]. 中华中医药学刊,2025,43(3):143-149.
[3] 李淑婷,李子郁,艾佳佳,等. 血液病患者造血干细胞移植后卵巢早衰激素替代治疗研究进展[J]. 中国妇产科临床杂志,2025,26(6):565-567.
[4] 胡菊,任涛涛,何文艳. 激素替代疗法联合左归丸加减治疗肾阴虚卵巢早衰的临床效果研究[J]. 海南医学,2023,34(21):3069-3073.
[5] 王玲玲,彭友晋,游维,等. 补肾疏肝方联合激素替代疗法治疗卵巢早衰合并负性情绪患者疗效及对性激素水平的影响[J]. 现代中西医结合杂志,2022,31(2):243-247.
[6] 谢幸.妇产科学[M].8 版.北京: 人民卫生出版社,2013:354-356.
[7] 李晓红,李芳,龙旭,等. 新加归肾丸联合雌二醇片/雌二醇地屈孕酮片对卵巢早衰患者卵巢功能、Kupperman评分的影响[J]. 中国性科学,2024,33(2):152-156.
[8] 宋慧,贾文娟. 二仙汤合右归汤治疗卵巢早衰闭经临床效果[J]. 辽宁中医杂志,2025,52(4):79-82.
[9] 徐晶,李莹. 疏肝补肾活血方联合激素替代治疗卵巢早衰的效果及其对卵巢储备功能和骨代谢的改善作用研究[J]. 中国性科学,2022,31(10):122-125.
[10] 蒋玲玲,汤卫春,康心怡,等. 坤泰胶囊联合雌孕激素替代疗法对卵巢早衰的疗效及对Treg、Th17、VEGF的影响[J]. 中药材,2023,46(9):2336-2340.
[11] 李江丽,刘群香. 激素替代法与坤泰胶囊联合治疗卵巢早衰患者的临床研究[J]. 北方药学,2022,19(5):42-44.
|
|
|
|
2026, Vol. 43 
